Baird analyst Catherine Schulte lowered the firm’s price target on Avantor to $22 from $24 and keeps an Outperform rating on the shares. The firm noted they reported 2Q results below expectations and lowered its 2023 outlook, noting incremental customer spending caution and deteriorating end-market conditions, primarily in bioproduction and biopharma research.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVTR: